China's National Medical Products Administration (NMPA) on Oct. 19 met to
advance its AI + drug regulation agenda, directing regulators to set rules,
steady expectations, enhance services and build an AI-enabled ecosystem to
support pharmaceutical innovation. The NMPA said it will draft special plans to
back priority tracks, shift review services upstream toward innovators, and
create an innovation-encouraging yet prudently risk-aware regulatory
environment; it called for using AI to improve drug-safety governance—making
reviews smarter, inspections and enforcement more precise, risk controls more
sensitive and coordinated supervision more efficient—and for establishing a
full-lifecycle, continuously iterated AI application management mechanism,
centralizing resources, training specialist talent, promoting
technology-for-good and safeguarding AI security standards.
